A New Cosmetic Ingredient Needs Defined Evidence
China's revised new-ingredient rules put composition, preparation, quality and safety information in the same development conversation. Requirements still depend on the ingredient and its risk category.
Define the ingredient before describing its promise
As of July 8, China’s revised requirements for cosmetic new-ingredient registration and filing were scheduled to take effect on July 15. The National Medical Products Administration (NMPA) order asks applicants to describe an ingredient’s characteristics and safe-use requirements on a scientific basis. Its core submission categories include a development report, preparation process, stability and quality-control research, and safety assessment. This is a rule for cosmetic new ingredients, not a general drug-approval pathway. [1]
The National Institutes for Food and Drug Control (NIFDC) issued a companion technical guideline. It distinguishes ingredients by source and preparation method as well as risk circumstance, then specifies the relevant technical materials. The work is therefore not one identical checklist for every ingredient. [2]
The dossier starts in the lab
For a complex ingredient, the development team needs to define what is actually being submitted: its principal components and proportions, preparation method, quality specifications, stability and intended safe-use conditions. Those choices influence what can be measured and how batches can be compared. If a carrier or mixed system is part of the ingredient, its role and composition must be described accurately; calling it a delivery technology does not remove the ingredient-specific evidence requirements. [1, 2]
The practical decision is early: agree on the ingredient’s identity and intended use before locking a manufacturing process or promising a product timeline. Evidence for a material’s composition and safety is not evidence that a finished skincare product works. Any product-performance claim needs its own appropriate evaluation.